[High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders].
This paper approaches in a critical way aspects of Brazilian public policies for drugs, emphasizing those classified as high cost and for rare diseases. The lysosomal storage diseases was taken as an example because of their rarity and the international trend for the development of new drugs for their treatment, all at high costs. Three lysosomal storage diseases were approached: Gaucher disease, Fabry disease and mucopolysaccharidosis type I. Gaucher disease has its treatment drug licensed in Brazil and guidelines for its use are established through a clinical protocol by the Ministry of Health. The others have their drug treatments registered in Brazil; however, no treatment guidelines for them have been developed by the government. The objective of the paper was to foster the discussion on the role of health technology assessment for high-cost drugs for rare diseases in Brazil, emphasizing the need for establishing health policies with legitimacy towards these diseases. Despite the difficulties in establishing a health policy for each rare disease, it is possible to create rational models to deal with this growing challenge.
Programa de Pós-Graduação em Ciências Médicas, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS. vsmonica@uol.com.br
Mônica Vinhas
MV
de Souza
Bárbara Corrêa
BC
Krug
Paulo Dornelles
PD
Picon
Ida Vanessa Doederlein
IV
Schwartz
D001938:Brazil; D003365:Costs and Cost Analysis; D000795:Fabry Disease / Q000188:drug therapy* / Q000191:economics*; D005776:Gaucher Disease / Q000188:drug therapy* / Q000191:economics*; D006291:Health Policy; D006801:Humans; D008059:Mucopolysaccharidosis I / Q000188:drug therapy* / Q000191:economics*; D009965:Orphan Drug Production / Q000191:economics*; D004364:Pharmaceutical Preparations / Q000191:economics*; D035583:Rare Diseases / Q000188:drug therapy* / Q000191:economics*
D004364:Pharmaceutical Preparations